Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis
Standard
Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis. / Schober, Sarah M; Peitsch, Wiebke K; Bonsmann, Gisela; Metze, Dieter; Thomas, Kai; Goerge, Tobias; Luger, Thomas A; Schneider, Stefan W.
In: J DTSCH DERMATOL GES, Vol. 12, No. 12, 12.2014, p. 1112-9.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis
AU - Schober, Sarah M
AU - Peitsch, Wiebke K
AU - Bonsmann, Gisela
AU - Metze, Dieter
AU - Thomas, Kai
AU - Goerge, Tobias
AU - Luger, Thomas A
AU - Schneider, Stefan W
N1 - © 2014 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
PY - 2014/12
Y1 - 2014/12
N2 - BACKGROUND AND OBJECTIVES: Progressive pigmented purpuric dermatosis (PPPD, Schamberg disease) is a rare benign, but chronic dermatosis frequently misdiagnosed as vasculitis or bleeding disorder. Although affected patients experience significant impairment in quality of life no effective treatment has been established. The aim of our two center case series was to evaluate efficacy and tolerability of the antioxidants rutoside and ascorbic acid as combination treatment for PPPD.PATIENTS AND METHODS: A retrospective review was performed on 35 patients with PPPD treated with 2 × 50 mg rutoside and 1,000 mg ascorbic acid daily between 2004 until 2011. The mean treatment duration was 8.2 months.RESULTS: 71.4% of the participants experienced complete clearance and 20.0% an improvement of more than 50%, accompanied by increased quality of life. Nine participants (25.1%) relapsed after discontinuation. In seven, rutoside and ascorbic acid was re-initiated, and all responded again. Only three participants reported mild adverse effects. Participants with shorter disease duration showed better therapeutic success, shorter time to response and lower risk of recurrence.CONCLUSION: Oral rutoside and ascorbic acid may be an efficient and well tolerated treatment for PPPD. Early treatment is recommended to achieve best clinical outcome.
AB - BACKGROUND AND OBJECTIVES: Progressive pigmented purpuric dermatosis (PPPD, Schamberg disease) is a rare benign, but chronic dermatosis frequently misdiagnosed as vasculitis or bleeding disorder. Although affected patients experience significant impairment in quality of life no effective treatment has been established. The aim of our two center case series was to evaluate efficacy and tolerability of the antioxidants rutoside and ascorbic acid as combination treatment for PPPD.PATIENTS AND METHODS: A retrospective review was performed on 35 patients with PPPD treated with 2 × 50 mg rutoside and 1,000 mg ascorbic acid daily between 2004 until 2011. The mean treatment duration was 8.2 months.RESULTS: 71.4% of the participants experienced complete clearance and 20.0% an improvement of more than 50%, accompanied by increased quality of life. Nine participants (25.1%) relapsed after discontinuation. In seven, rutoside and ascorbic acid was re-initiated, and all responded again. Only three participants reported mild adverse effects. Participants with shorter disease duration showed better therapeutic success, shorter time to response and lower risk of recurrence.CONCLUSION: Oral rutoside and ascorbic acid may be an efficient and well tolerated treatment for PPPD. Early treatment is recommended to achieve best clinical outcome.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Ascorbic Acid
KW - Child
KW - Drug Therapy, Combination
KW - Female
KW - Germany
KW - Humans
KW - Male
KW - Middle Aged
KW - Pigmentation Disorders
KW - Purpura
KW - Retrospective Studies
KW - Rutin
KW - Treatment Outcome
KW - Young Adult
KW - Journal Article
KW - Multicenter Study
KW - Research Support, Non-U.S. Gov't
U2 - 10.1111/ddg.12520
DO - 10.1111/ddg.12520
M3 - SCORING: Journal article
C2 - 25482694
VL - 12
SP - 1112
EP - 1119
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 12
ER -